AstraZeneca applies for approval of antibody treatment that provides passive immunity against COVID-19 for up to a year according to the press release. Indicated for vulnerable people who are immunocompromised or who have not responded to the vaccine.

Dr. Barry Dworkin

Medical Mythbusting Commentary for November 4, 2021

AstraZeneca applies for approval of antibody treatment that provides passive immunity against COVID-19 for up to a year according to the press release. Indicated for vulnerable people who are immunocompromised or who have not responded to the vaccine. Play Now | Play in Popup | Download

Source:
Health Canada to review AstraZeneca’s antibody therapy that could prevent COVID-19

Related posts:

  1. Will Covid vaccine mixing be adopted as health policy? They use different delivery systems carrying the genetic instruction set to produce the same spike protein, ergo ongoing studies are evaluating clinical outcomes to determine if assumption is true.
  2. For those who have had AstraZeneca as their first dose, small Spanish study shows that using Pfizer as the second dose is safe and effective. More evaluation and other trials are ongoing but still, good news.
  3. Universal flu vaccine in development. Clinical trial to start in the UK.
  4. Israeli study offers more evidence of Pfizer vaccine efficacy with 94% drop in symptomatic cases and 92% decrease in severe illness in people aged 55 and older.—- Restriction-easing plan in Ontario risks Yo-Yo effect once again.
Bitnami